Report

infectious disease therapeutics market

Infectious Disease Therapeutics Market on the basis of Mode of Treatment (Drugs and Vaccines), Disease Indication (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others), Distribution Channel (hospital pharmacy, retail pharmacy, and Others) and Geography – Global Forecast up to 2027

pages Pages: 82
tables Tables: 94
charts Charts: 64
country Regions/Countries: 4 / 10
compaines Companies: 10
enqhours Enquiry Hours: 10
  • Get Free 10% Customization in this Report

COVID - 19

Covid impact updated reports at special price

Infectious diseases are commonly caused by pathogenic microorganisms such as viruses, bacteria, fungi, and parasites. These diseases are transferred from one individual to the other by direct or indirect contact. Anti-infective drugs prevent the growth of such diseases. These drugs act by a mechanism of the host defense system, which specifically targets the causative agent. Infectious diseases including HIV, malaria, tuberculosis, influenza, hepatitis A and hepatitis C are acute diseases causing notable deaths globally. One of the key factors driving the infectious disease therapeutics market is the growing number of infectious diseases worldwide, which has created a demand for infectious disease therapeutics. Moreover, the favorable reimbursement policies for infectious diseases and the surging consumption of anti-microbial direct-acting drugs are few other factors accountable for the significant growth of the infectious disease therapeutics market in the forecast period. However, the limited number of skilled persons in manufacturing effective drugs is a key factor negatively impacting the market growth. The Infectious Disease Therapeutics Market is anticipated to grow at the rate of 8.9% CAGR by 2027. 

Research Methodology:

The Infectious Disease Therapeutics Market has been analyzed by utilizing the optimum combination of secondary sources and in-house methodology and a unique balance of primary insights. The real-time valuation of the market is an integral part of our forecasting and market sizing methodology. Industry experts and our primary participants have helped to compile related aspects with accurate parametric estimations for a complete study. The primary participants share is given below:

Infectious Disease Therapeutics Market

Infectious Disease Therapeutics Market on the basis of Mode of Treatment

  • Drugs
  • Vaccines

Infectious Disease Therapeutics Market on the basis of Disease Indication

  • Tuberculosis
  • HIV/AIDS
  • Influenza
  • Hepatitis
  • Others

Infectious Disease Therapeutics Market on the basis of Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Infectious Disease Therapeutics Market on the basis of Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Based on the mode of treatment, the infectious disease therapeutics market is bifurcated into drugs and vaccines. The drug mode of treatment is projected to have a significant share in the market. This is because the increasing population of old around the world is a major attribute to augmenting segment growth. Furthermore, the growing expenditure on healthcare, particularly in the developed countries, is also surging the segment growth.

Based on the disease indication, the infectious disease therapeutics market is segmented by Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others. The hepatitis segment is expected to register the highest growth rate in the coming years. The increasing incidence of hepatitis, growing clinical trial activities for the advent of new drugs, and a rising number of initiatives to elevate the adoption of drugs are projected to be the factors responsible for the segment's growth.

Further, the infectious disease therapeutics market is divided into hospital pharmacy, retail pharmacy, and others based on the distribution channel. The hospital pharmacy segment held the maximum share in the market. This is ascribed to the increase in hospital construction with the advanced equipment, and availability of professionals in the hospitals are the key factors.

In the geography market, the geographical regions are categorized into North America, Europe, Asia Pacific, and the rest of the world. Among all the regions, North America has acquired a leading share in the market. Increasing incidence of infectious diseases and favorable reimbursement scenarios are key factors expected to boost infectious disease therapeutics in the region.

The global market for infectious disease therapeutics is significantly driven by the surging number of infectious diseases worldwide, which has surged the demand for therapeutics for infectious diseases. The key reason for the rising number of infectious diseases is the increasing population worldwide, specifically in developing countries including Japan, India, and many other countries.

Top competitors operating in the global infectious disease therapeutics market are Gilead Sciences, Inc., BioCryst Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., Johnson & Johnson, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Janssen Pharmaceutical, Novartis International AG and Astellas Pharma.

Henceforth, the vital burden on public health is presented by various infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, hepatitis C, hepatitis C, and influenza. Therefore, most of the deaths are caused due to infectious diseases where new therapeutics such as drugs and vaccines are having a prominent role in preventing these diseases.

  • This study consists of information such as infectious disease therapeutics market dynamics scenarios and opportunities over the forecast period.
  • The report provides regional, sub-regional, and country-level analysis, including the demand and supply forces and their influence on the infectious disease therapeutics market.
  • The competitive landscape includes the share of key players, new developments, and strategies in the past few years.
  • This report also includes the comprehensive companies providing products, relevant financial information, recent developments, SWOT analysis, and strategies by these infectious disease therapeutics market players.

 

  1. Executive Summary
  2. Industry Outlook
    1. Industry Overview
    2. Industry Trends
  3. Market Snapshot
    1. Market Definition
    2. Market Outlook
      1. Porter Five Forces
    3. Related Markets
  4. Market characteristics
    1. Market Overview
    2. Market Segmentation
    3. Market Dynamics
      1. Drivers
      2. Restraints
      3. Opportunities
    4. DRO - Impact Analysis
  5. Mode of Treatment: Market Size & Analysis
    1. Overview
    2. Drugs
    3. Vaccines
  6. Disease Indication: Market Size & Analysis
    1. Overview
    2. Tuberculosis
    3. HIV/AIDS
    4. Influenza
    5. Hepatitis
    6. Others
  7. Distribution Channel: Market Size & Analysis
    1. Overview
    2. Hospital Pharmacy
    3. Retail Pharmacy
    4. Others
  8. Geography: Market Size & Analysis
    1. Overview
    2. North America
    3. Europe
    4. Asia Pacific
    5. Rest of the World
  9. Competitive Landscape
    1. Competitor Comparison Analysis
    2. Market Developments
      1. Mergers and Acquisitions, Legal, Awards, Partnerships
      2. Product Launches and execution
  10. Vendor Profiles
    1. Gilead Sciences, Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    2. BioCryst Pharmaceuticals, Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    3. F. Hoffmann-La Roche AG
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    4. Merck & Co., Inc.
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    5. Johnson & Johnson
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    6. Boehringer Ingelheim GmbH
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    7. GlaxoSmithKline plc
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    8. Janssen Pharmaceutical
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    9. Novartis International AG
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
    10. Astellas Pharma
      1. Overview
      2. Financial Overview
      3. Product Offerings
      4. Developments
      5. Business Strategy
  11. Analyst Opinion
  12. Annexure
    1. Report Scope
    2. Market Definitions
    3. Research Methodology
      1. Data Collation and In-house Estimation
      2. Market Triangulation
      3. Forecasting
    4. Report Assumptions
    5. Declarations
    6. Stakeholders
    7. Abbreviations

TABLE 1.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 2.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR DRUGS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR TUBERCULOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HIV/AIDS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 8.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9.           GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10.         GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 11.         GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR HOSPITAL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 12.         GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR RETAIL PHARMACY, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 13.         GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 14.         NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 15.         NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 16.         NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 17.         NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18.         U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 19.         U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 20.         U.S INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21.         CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 22.         CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 23.         CANADA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 24.         EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 25.         EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 26.         EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 27.         EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28.         GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 29.         GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 30.         GERMANY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31.         U.K INFECTIOUS DISEASE THERAPEUTICS  MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 32.         U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 33.         U.K INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34.         FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 35.         FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 36.         FRANCE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37.         ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 38.         ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 39.         ITALY INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40.         SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 41.         SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 42.         SPAIN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43.         ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 44.         ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 45.         ROE INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 46.         ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 47.         ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 48.         ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 49.         ASIA PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50.         CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 51.         CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 52.         CHINA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53.         INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 54.         INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 55.         INDIA INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56.         JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 57.         JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 58.         JAPAN INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59.         REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 60.         REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 61.         REST OF APAC INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62.         REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY MODE OF TREATMENT, 2021-2027 (USD BILLION)

TABLE 63.         REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISEASE INDICATION, 2021-2027 (USD BILLION)

TABLE 64.         REST OF WORLD INFECTIOUS DISEASE THERAPEUTICS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 65.         GILEAD SCIENCES, INC: FINANCIALS  

TABLE 66.         GILEAD SCIENCES, INC: PRODUCTS & SERVICES        

TABLE 67.         GILEAD SCIENCES, INC: RECENT DEVELOPMENTS       

TABLE 68.         BIOCRYST PHARMACEUTICALS, INC: FINANCIALS        

TABLE 69.         BIOCRYST PHARMACEUTICALS, INC: PRODUCTS & SERVICES  

TABLE 70.         BIOCRYST PHARMACEUTICALS, INC: RECENT DEVELOPMENTS 

TABLE 71.         F. HOFFMANN-LA ROCHE AG: FINANCIALS       

TABLE 72.         F. HOFFMANN-LA ROCHE AG: PRODUCTS & SERVICES 

TABLE 73.         F. HOFFMANN-LA ROCHE AG: RECENT DEVELOPMENTS

TABLE 74.         MERCK & CO., INC: FINANCIALS          

TABLE 75.         MERCK & CO., INC: PRODUCTS & SERVICES    

TABLE 76.         MERCK & CO., INC: RECENT DEVELOPMENTS   

TABLE 77.         JOHNSON & JOHNSON: FINANCIALS    

TABLE 78.         JOHNSON & JOHNSON: PRODUCTS & SERVICES          

TABLE 79.         JOHNSON & JOHNSON: RECENT DEVELOPMENTS         

TABLE 80.         BOEHRINGER INGELHEIM GMBH: FINANCIALS 

TABLE 81.         BOEHRINGER INGELHEIM GMBH: PRODUCTS & SERVICES       

TABLE 82.         BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS      

TABLE 83.         GLAXOSMITHKLINE PLC: FINANCIALS  

TABLE 84.         GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES        

TABLE 85.         GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS       

TABLE 86.         JANSSEN PHARMACEUTICAL: FINANCIALS       

TABLE 87.         JANSSEN PHARMACEUTICAL: PRODUCTS & SERVICES  

TABLE 88.         JANSSEN PHARMACEUTICAL: RECENT DEVELOPMENTS

TABLE 89.         NOVARTIS INTERNATIONAL AG: FINANCIALS   

TABLE 90.         NOVARTIS INTERNATIONAL AG: PRODUCTS & SERVICES         

TABLE 91.         NOVARTIS INTERNATIONAL AG: RECENT DEVELOPMENTS        

TABLE 92.         ASTELLAS PHARMA: FINANCIALS         

TABLE 93.         ASTELLAS PHARMA: PRODUCTS & SERVICES   

TABLE 94.         ASTELLAS PHARMA: RECENT DEVELOPMENTS  

Research Framework

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting
Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources

Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources

Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.

outicon

Infectious Disease Therapeutics Market on the basis of Mode of Treatment (Drugs and Vaccines), Disease Indication (Tuberculosis, HIV/AIDS, Influenza, Hepatitis, and Others), Distribution Channel (hospital pharmacy, retail pharmacy, and Others) and Geography – Global Forecast up to 2027
Interested in this report?
Get your FREE sample now!
DOWNLOAD NOW

Select User License

$
Request For Sample Report
Enquire Before Buying

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer 10% worth of FREE customization at the time of purchase

Speak to our analyst
Related Reports
Card image cap
Genital Herpes Treatment Market by Type of Drugs (Acyclovir,...
$ 4000
Card image cap
Compounding Pharmacy Market by Therapeutic Areas (Hormone Re...
$ 4000
Card image cap
Attention Deficit Hyperactivity Market by Drug Type (Stimula...
$ 4000
Card image cap
Heparin Sales Market By Type (Low Molecular Weight Heparin, ...
$ 4000
Card image cap
Vaccine Market By Technology Type (Recombinant, Conjugate Va...
$ 4000
Card image cap
Yeast Infection Market based on Pathogen Type (Candida albic...
$ 4000